Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Maintenance in Metastatic Nasopharyngeal Carcinoma
NCT03180476Phase 2Completed
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in nasopharyngeal carcinoma (NPC), sponsored by Sichuan Cancer Hospital. Started Apr 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03180476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180476.